在内血管治疗之前的桥梁血栓溶解与大心脏梗塞核心患者的更好的结果有关
Yu Guo1, Yong-Gang Xu2, Chao Liu2
1Department of Neurosurgery, Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou, China.
Journal of neurointerventional surgery
|August 9, 2024
概括
在内血管治疗 (EVT) 之前弥合静脉内血栓溶解 (IVT) 改善了大发心脏病核心中风患者的功能结果. 然而,这种方法增加了症状性内出血 (sICH) 的风险.
科学领域:
- 神经学 神经学
- 干预神经病学 干预神经病学
- 脑卒中医学 脑卒中医学
背景情况:
- 大型心脏梗塞核心中风带来了独特的治疗挑战.
- 内血管治疗 (EVT) 是主要的治疗方法,但可以改善结果.
- 研究诸如静脉血栓溶解 (IVT) 等辅助疗法至关重要.
研究的目的:
- 为了比较桥接IVT后的EVT与单独EVT的有效性和安全性.
- 评估大型缺血性中风核心 (ASPECTS ≤5或核心体积 ≥50毫升) 的患者的结果.
主要方法:
- 一个系统的文献综述和对2015年1月至2024年6月期间发表的研究的元分析.
- 搜索的数据库:PubMed,EMBASE和科克兰图书馆.
- 分析了9项涉及2641名患者的观察性研究的数据,重点关注功能结果,再输血,SICH和死亡率.
主要成果:
- 与单独使用EVT相比,桥接IVT + EVT显著改善了90天的功能独立性 (mRS 0-2) 和整体功能结果 (mRS 0-3).
- 两组之间在成功的再输血率或90天死亡率上没有发现显著差异.
- IVT + EVT 组显示症状性内出血 (sICH) 的发生率较高.
结论:
- 在EVT之前跨越IVT与患有大心脏梗塞核心中风的患者的更好的功能结果有关.
- 尽管结果有所改善,但必须考虑与桥梁疗法相结合的sICH风险增加.
- 需要进一步的随机对照试验来验证这些发现.
相关概念视频
01:17Ischemic Heart Disease: Overview
1.2K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.2K
01:16Clot Retraction and Fibrinolysis
5.1K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.1K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
164
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
164